Stock KH6 NEWAMSTERDAM PHARMA COMPANY N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus NewAmsterdam Pharma Company N.V. BOERSE MUENCHEN

Equities

KH6

NL00150012L7

Market Closed - BOERSE MUENCHEN
Other stock markets
 15:43:44 2024-06-25 EDT 		5-day change 1st Jan Change
18.3 EUR 0.00% Intraday chart for NewAmsterdam Pharma Company N.V. +7.65% 0.00%
06-11 NewAmsterdam Pharma Gets Another US Patent Extending IP Protection for Obicetrapib Until July 2043 MT
06-10 Transcript : NewAmsterdam Pharma Company N.V. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 10:40 AM

Evolution of the average Target Price on NewAmsterdam Pharma Company N.V.

Price target over the last 5 years

History of analyst recommendation changes

8f3c1af0e11ef99f3dd02d4aef.WfzzzquE_uGNGUbqxsUpvT98ittwhhbTsa-0vg1ObXo.Lr65pOzMy5HsURy6hfVN03o165Ax1y-h8O2F-UsADBEQq6aGmOCJrsUpAw~da716b896575e6983f2fd93b74df9a96

Analyst Recommendations on NewAmsterdam Pharma Company N.V.

TD Cowen Starts NewAmsterdam Pharma With Buy Rating MT
Scotiabank Starts NewAmsterdam Pharma With Sector Outperform Rating, $35 Price Target MT
RBC Raises Price Target on NewAmsterdam Pharma to $31 From $25, Keeps Outperform, Speculative Risk MT
Guggenheim Starts NewAmsterdam Pharma With Buy Rating, $30 Price Target MT
RBC Initiates NewAmsterdam Pharma at Outperform With Speculative Risk Qualifier, $25 Price Target MT
Credit Suisse Lifts NewAmsterdam Pharma's Price Target to $22 From $21, Keeps Outperform Rating MT
Credit Suisse Starts NewAmsterdam Pharma at Outperform With $21 Price Target MT
SVB Securities Initiates Coverage on NewAmsterdam Pharma With Outperform Rating, $19 Price Target MT
SVB Securities Starts NewAmsterdam Pharma at Outperform With $19 Price Target MT
William Blair Starts NewAmsterdam Pharma at Outperform MT
Jefferies Starts NewAmsterdam Pharma at Buy With $24 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
18.38 EUR
Average target price
35.19 EUR
Spread / Average Target
+91.49%
High Price Target
46.62 EUR
Spread / Highest target
+153.65%
Low Price Target
27.86 EUR
Spread / Lowest Target
+51.57%

Consensus detail

Consensus revision (last 18 months)

Analysts covering NewAmsterdam Pharma Company N.V.

TD Cowen
Scotiabank
RBC Capital Markets
Guggenheim
Credit Suisse
SVB Securities LLC
Jefferies & Co.
William Blair & Co.

Ratings for NewAmsterdam Pharma Company N.V.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. NAMS Stock
  4. KH6 Stock
  5. Consensus NewAmsterdam Pharma Company N.V.